The RADAR Study: Week 48 Safety and Efficacy of RAltegravir Combined with Boosted DARunavir Compared to Tenofovir/Emtricitabine Combined with Boosted Darunavir in Antiretroviral-Naive Patients. Impact on Bone Health

BACKGROUND: NRTI-sparing regimens may avoid long-term mitochondrial, bone and renal toxicities and maintain viral suppression. METHODS: In the RADAR study, 85 antiretroviral-naïve HIV-infected patients were randomized to receive either raltegravir (RAL) (n = 42) or tenofovir/emtricitabine (TDF/FTC)...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Bedimo, Roger J., Drechsler, Henning, Jain, Mamta, Cutrell, James, Zhang, Song, Li, Xilong, Farukhi, Irfan, Castanon, Rosinda, Tebas, Pablo, Maalouf, Naim M.
Médium: Artigo
Jazyk:Inglês
Vydáno: Public Library of Science 2014
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4149560/
https://ncbi.nlm.nih.gov/pubmed/25170938
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0106221
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky